Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Vcanbio-backed cancer diagnostics technology provider has filed to go public in the US having raised another $71m from investors including Alexandria Venture Investments.

Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.

BlueCross BlueShield Venture Partners invested as health management software provider Wellframe boosted its overall funding to $45m.

SV Health Investors and Genesys Capital have co-led a series A round for University of Toronto’s EBT Medical, which is progressing a neuromodulation technique to treat pelvic floor disorders.

MIT-founded regenerative polymer developer Tissium will put the capital into clinical-stage development and toward regulatory clearance in multiple markets.

The immuno-oncology therapy developer has launched with $56m in series A funding from investors including Taiho Ventures and UPMC enterprises.

Wearable health tracker developer Biovotion has been bought by digital therapeutics producer Biofourmis, enabling Swiss Re and STMicroelectronics to exit.

Ryan Miller has moved from a role overseeing corporate venturing and M&A at Anthem to a corporate development position at Change Healthcare.